Friday, April 13, 2012
Japan - Takeda Joins International Open-Source Drug Research Consortium
Takeda Pharma has joined the Structural Genomics Consortium to fund collective drug research aimed at bringing new, more effective medicines to market faster.
Takeda Pharmaceutical Company Limited has joined theStructural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster.
The SGC, a not-for-profit organization based at the Universities of Toronto, Canada, and Oxford, England, supports the discovery of new medicines by more than 200 scientists from academia and industry who make all early-stage research openly available with no patents or restrictions.
Takeda’s contribution raises the total from US$13 million to US$50 million in support of the SGC by six of the world’s leading pharmaceutical companies. Takeda will also participate on the SGC Scientific Committee and its Board of Directors.
“As a global leader in research, Takeda is dedicated to helping change the way drug discovery is conducted,” said Paul Chapman, General Manager, Pharmaceutical Research Division, Takeda.
“We are very excited about the opportunity to become a part of the SGC, and firmly believe that important new medicines will be discovered in industry and vital scientific knowledge will be gained in academia through this open innovation.”
Source: Takeda Pharmaceutical Co.